In fact, they were slowing down development and sourcing efforts ... maybe by celebrating wins or milestones. “As long as they see the value and the benefit at the end, you can maintain that momentum.

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...

First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - ...